The Next Aim Stock MY opinion. God Knows Best

[The Next Aim Stock MY opinion. God Knows Best @Anwar11Zee]

https://t.co/KA0g5uuXOo
THE ABOVE LINK IS WELL WORTH LOOKING AT FOR CATENAI.

[The Next Aim Stock MY opinion. God Knows Best @Anwar11Zee]

UKOG ɓuys picking up nicely. Just a waiting game now

[UKOG @UKOGlistedonAIM]

HORSE HILL SALE: UK Oil & Gas has agreed £1 million sale of entire 85.635% interest in Horse Hill field to Energy B PLC, oil and gas company listed on London Aquis exchange. https://t.co/iGJLpSFOwi #oil #AIM #energy

[Afzal Valli @AfzalValli]

#VAL

Worth a listen

@valirxplc CEO took a asset in U.S at $250m market cap in 2010

https://t.co/9MJAGzWmfW

[Afzal Valli @AfzalValli]

#VAL

ValiRx also continues advancing several oncology-focused programmes targeting areas of significant unmet medical need. Its Cytolytix oncolytic peptide programme is focused on triple negative breast cancer, while the VAL201 programme, now housed within Blue Ribbon Bio, is being developed primarily for prostate cancer alongside additional applications in breast cancer and endometriosis.

Eccleston stated that many of the company’s therapeutic assets possess “multi cancer potential,” allowing multiple indications to be pursued using shared mechanisms and development pathways.

Looking ahead, the company expects several potential catalysts over the coming months. These include decisions regarding new in-licensing opportunities, patent developments linked to Cytolytix assets, and outcomes from multiple grant funding applications.

Eccleston said ValiRx was awaiting results from several major funding applications between July and year-end, including six-figure and seven-figure grant opportunities. He suggested that successful outcomes from these programmes, including European funding initiatives, could prove transformational for the company’s future development plans.

https://t.co/mm8drOVjfG

[Afzal Valli @AfzalValli]

#VAL

WHAT A BARGAIN …

Just over £2m Market Cap with a healthy cash balance of £1.15m

Nice listen 8 min on what’s expected 👌

https://t.co/jH15zKOZf8

News on ..

🔷Decision on a In licensing
🔷IP portfolio expansion/patents
🔷Preclinical development and expansion of ValiRx Animal Health
🔷Several big grants transformational 6-7 figure grants

[Afzal Valli @AfzalValli]

#CTAI 💪 So undervalued and what a opportunity

[Afzal Valli @AfzalValli]

#CTAI

CATENAI PLC - Klarian Update https://t.co/coJjSw7Zn6 via @YouTube

[RC @rc_surrey]

@AfzalValli @TalismanMetals #TLM hopefully into double digits by end of the month🤞

[The Next Aim Stock MY opinion. God Knows Best @Anwar11Zee]

CTAI....The buying is strong.

[The Next Aim Stock MY opinion. God Knows Best @Anwar11Zee]

CTAI is priming for a share price rise. Watch this space

[Afzal Valli @AfzalValli]

#CTAI

Klarian has advised the Company that it is in discussions with investors and has made significant advancements with its commercial sales pipeline, which now exceeds £5 million. It is also in the final stages of agreeing a Statement of Work contract with a global provider of technology solutions to companies operating in the energy and natural resources sectors, with whom Klarian has an existing MOU.

Klarian has also informed the Company that it has already conducted product demonstrations with customers of its MOU partner and has received strong interest from two international, upstream energy companies for its recently launched Virtual Sensor product (Vesta), with further discussions now being accelerated. Vesta enables pipeline operators to deploy virtual sensors across their infrastructure at a significantly lower cost than physical sensors, providing enhanced visibility into network performance.

[The Next Aim Stock MY opinion. God Knows Best @Anwar11Zee]

Def something happening. Ready for the rise

[Afzal Valli @AfzalValli]

#NFX

Huge upside on licensing deal

The deals illustrate the potential of NXP002 treatment of IPF PPF

RedX to AstraZeneca/2020 $377m

Galecto/ Galectin-3 to Bristol Myers Squibb $444m

Promedior to Bristol Myers Squibb/2015Roche/2020 
$1,250 $1,390

Multiple parties interested

[The Next Aim Stock MY opinion. God Knows Best @Anwar11Zee]

Rockfire latest news
https://t.co/ODzioX2V2S

[Afzal Valli @AfzalValli]

#VAL

Now funded for the remainder of 2026 and a plan set out with a avalanche of news flow 👇

ValiRx seeks to unlock the substantial potential of early-stage innovation and provide a specialist service for its in-house collaborative projects and third-party innovators through its subsidiary, Inaphaea Biolabs Limited ("Inaphaea").

The Company is focused on a number of near-term operational objectives which may provide potential value inflection points. These include the grant of Cytolytix patents and the filing of new intellectual property, supporting the continued expansion of the Group's intellectual property portfolio; validation of the primary indication for ValiRx Animal Health, with the potential to support external investment and clinical partnering opportunities; and the progression of multiple non-dilutive funding applications, with read-outs expected between July and November 2026.

In addition, the Company is seeking to validate VAL201 2.0 and make associated patent filings, which may further extend the Group's intellectual property portfolio and support potential external investment into Blue Ribbon Bio. The Company is also progressing the establishment of a special purpose vehicle and the in-licensing of the McGill asset, with the potential for a cross-licence to ValiRx Animal Health and external co-development. The Company also expects to complete the 3K screen repurposing selection process and provide a results read-out, which may support future grant funding and/or a partnered asset opportunity.

[🇬🇧 𝑻𝒉𝒆 𝑫𝒐𝒄 🇨🇾 @DDS_DocHoliday]

Please can you go to 25p for another £1m #KEN 🤣🤣🤣 its only £85m mcap yano!!!

[Arkadian Strategic Metals Plc @ArkadianMetals]

In many geological systems, niobium and zirconium are treated as relatively stable markers. They do not usually move easily through fluids. At the Motzfeldt Project in South Greenland, the latest Merino results point to a more unusual geological setting.

https://t.co/smfZMgTAdh

#AlbaMineralResources #CriticalMinerals #RareEarths #Niobium #Zirconium #ResponsibleExploration #Greenland

[Vox Markets @VOXmarkets]

Cadence Minerals Plc: Grant of Installation Licence at Amapa

Hear more from Kiran Morzaria, CEO of Cadence Minerals

▶️ Watch the full interview: https://t.co/KdyVezWAUd

🎧 Also available to listen to on The Vox Markets Podcast

@CadenceMinerals #KDNC #ironore #brazil #mining

[Afzal Valli @AfzalValli]

#KEN

Thanks again for sharing @KendrickRes @RoastPR

What a GEM we have here

Mentioned to be worth in $billions and so many parties are interested and in talks 👌

[The Next Aim Stock MY opinion. God Knows Best @Anwar11Zee]

Rockfire is another stock priming to be a multibagger

[Rockfire Resources plc (LON:ROCK) @Rockfireplc]

1/7 - Drilling update from Molaoi 👇

A pXRF reading of 54.3% Zn has just been recorded in hole HMO-016 at 314.5m depth.

That's the second-highest zinc grade ever encountered at the project.

Here's what we've found, and what's next.

#ROCK

[Afzal Valli @AfzalValli]

Surely was RNS of the DAY

#KEN @KendrickRes

[The Next Aim Stock MY opinion. God Knows Best @Anwar11Zee]

KENDRICK news is pointing at mega profits to come for us shareholders

[Darren-Uk Trading. @Darrenukdaytra1]

#KEN full retrace complete. Now into all time highs and the 1.618fib extension. Looking good. DYOR